Literature DB >> 22924923

Real-time PCR to quantify Leishmania donovani in hamsters.

Anuradha Srivastava1, J Mark Sweat, Azliyati Azizan, Brian Vesely, Dennis E Kyle.   

Abstract

Visceral leishmaniasis, a vector-borne disease caused by Leishmania donovani and Leishmania infantum , currently affects 12 million individuals in 88 countries. In the present study, a real-time PCR (rt-PCR) assay has been optimized and validated against 2 other routine methods, i.e., microscopy and limiting dilution culture assay, to estimate parasite load in the liver of infected Syrian hamsters (Mesocricetus auratus). A set of specific primers amplified a 116-bp target template of the kinetoplastid DNA of L. donovani in a SYBR® Green-based rt-PCR assay. To assess the methods, we tested 2 anti-leishmanial compounds belonging to the class of arylimidamides, DB745 (2,5-bis[2-ethoxy-4-(2-pyridylimino)aminophenyl]furan) and DB766 (2,5-bis[2-(2-propoxy)-4-(2-pyridylimino)aminophenyl]furan) for efficacy in vivo in Syrian hamsters infected with L. donovani promastigotes. Parasite load was quantified in liver by all 3 methods and was found comparable. Of the 3 methods, rt-PCR was the fastest and most convenient, sensitive, and reproducible method.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22924923     DOI: 10.1645/GE-3221.1

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  8 in total

1.  Inadequacy of 12-Week Miltefosine Treatment for Indian Post-Kala-Azar Dermal Leishmaniasis.

Authors:  Susmita Ghosh; Nilay Kanti Das; Shibabrata Mukherjee; Debanjan Mukhopadhyay; Jayashree Nath Barbhuiya; Avijit Hazra; Mitali Chatterjee
Journal:  Am J Trop Med Hyg       Date:  2015-07-14       Impact factor: 2.345

2.  Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.

Authors:  Eline Eberhardt; Annelies Mondelaers; Sarah Hendrickx; Magali Van den Kerkhof; Louis Maes; Guy Caljon
Journal:  Parasitol Res       Date:  2016-07-13       Impact factor: 2.289

3.  Mobile suitcase laboratory for rapid detection of Leishmania donovani using recombinase polymerase amplification assay.

Authors:  Dinesh Mondal; Prakash Ghosh; Md Anik Ashfaq Khan; Faria Hossain; Susanne Böhlken-Fascher; Greg Matlashewski; Axel Kroeger; Piero Olliaro; Ahmed Abd El Wahed
Journal:  Parasit Vectors       Date:  2016-05-13       Impact factor: 3.876

4.  Development of real-time PCR assays for evaluation of immune response and parasite load in golden hamster (Mesocricetus auratus) infected by Leishmania (Viannia) braziliensis.

Authors:  Raquel Peralva Ribeiro-Romão; Andrea Franco Saavedra; Alda Maria Da-Cruz; Eduardo Fonseca Pinto; Otacilio C Moreira
Journal:  Parasit Vectors       Date:  2016-06-27       Impact factor: 3.876

5.  A real-time PCR assay for quantification of parasite burden in murine models of leishmaniasis.

Authors:  Alejandro L Antonia; Liuyang Wang; Dennis C Ko
Journal:  PeerJ       Date:  2018-11-09       Impact factor: 2.984

6.  Evaluation of synergistic therapeutic effect of shark cartilage extract with artemisinin and glucantime on visceral leishmaniasis in BALB/c mice.

Authors:  Soheila Molaie; Fatemeh Ghaffarifar; Abdohosein Dalimi; Mohammad Hassan Zuhair; Zohreh Sharifi
Journal:  Iran J Basic Med Sci       Date:  2019-02       Impact factor: 2.699

7.  Usefulness of kDNA PCR in the diagnosis of visceral leishmaniasis reactivation in co-infected patients.

Authors:  Antonio Carlos Nicodemo; Valdir Sabbaga Amato; Felipe Francisco Tuon; Regina Maia de Souza; Thelma Suely Okay; Lúcia Maria Almeida Braz
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2013 Nov-Dec       Impact factor: 1.846

8.  Comparison of Parasite Burden Using Real-Time Polymerase Chain Reaction Assay and Limiting Dilution Assay in Leishmania major Infected Mouse.

Authors:  Somayeh Ghotloo; Mostafa Haji Mollahoseini; Ali Najafi; Farshid Yeganeh
Journal:  Iran J Parasitol       Date:  2015 Oct-Dec       Impact factor: 1.012

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.